NATCO PHARMA
|
The Current P/E Ratio of NATCO PHARMA is 13.60.
| Share Price | ₹1,172.7 | May 21,2026 |
| Market Cap | ₹21,002.2 Cr | |
| Earnings-TTM | ₹1,544.6 Cr | TTM-Consolidated Results |
| Price/Earnings | 13.60x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NATCO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹21,002.2 Cr] as on May 21,2026
(/) Earnings [ ₹1,544.6 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 13.60x ]
Thus, for NATCO PHARMA , the investors are currently willing to pay 13.60 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NATCO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NATCO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of NATCO PHARMA
PE Ratio Performance Analysis for NATCO PHARMA
- NATCO PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 29.94x.
- NATCO PHARMA 's operated at median p/e ratio of 14.38x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NATCO PHARMA 's p/e ratio peaked in Mar2022 at 81.3x.
- NATCO PHARMA 's p/e ratio hit its five-year low in Mar2025 of 7.57x.
How does NATCO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NATCO PHARMA | 1,544.60 | 13.60 | 21,002.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 41.24 | 453,750.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 73.46 | 182,117.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 66.60 | 151,314.0 |
| CIPLA LTD | 3,869.79 | 29.26 | 113,225.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.55 | 110,037.0 |
| MANKIND PHARMA LTD | 1,926.41 | 53.91 | 103,845.0 |
| LUPIN LTD | 5,355.47 | 19.51 | 104,490.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 20.74 | 104,266.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 25.33 | 88,979.3 |
| LAURUS LABS LTD | 889.85 | 81.94 | 72,918.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NATCO PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 13.60x |
| Max industry PE | 81.94x |
| Median industry PE | 29.26x |
| Average industry PE | 41.10x |
You may also like the below Video Courses